Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

SHR-2554

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Jiangsu Hengrui Pharma, Treeline Biosci

Drug class:

EZH2 inhibitor

Related drugs:

SMARCB1 deletion	Soft Tissue Sarcoma	SMARCB1 deletion	Soft Tissue Sarcoma	SHR-2554 Sensitive: C3 – Early Trials SHR-2554 Sensitive : C3	SHR-2554 Sensitive: C3 – Early Trials SHR-2554 Sensitive : C3
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	SHR-2554 Sensitive: D – Preclinical SHR-2554 Sensitive : D	SHR-2554 Sensitive: D – Preclinical SHR-2554 Sensitive : D
EZH2 mutation	Diffuse Large B Cell Lymphoma	EZH2 mutation	Diffuse Large B Cell Lymphoma	chidamide + SHR-2554 Sensitive: D – Preclinical chidamide + SHR-2554 Sensitive : D	chidamide + SHR-2554 Sensitive: D – Preclinical chidamide + SHR-2554 Sensitive : D